Ollin Biosciences

Redefining what’s possible in ophthalmology

[Ollin Biosciences @OllinBio]

We’re excited to join the #retina community at @asrsdocs! On Thursday, two members of our SAB will present our head-to-head Phase 1b JADE data evaluating OLN324 versus faricimab (Vabysmo®): David Eichenbaum on wAMD, and Veeral Sheth on DME. https://t.co/AK185WaTCL

[Ollin Biosciences @OllinBio]

Looking back at #CTS2026: Dr. Margaret Chang presented 20-week JADE trial data showing OLN324 achieved faster and greater retinal drying vs. faricimab in #DME, with 93% of patients needing no retreatment after week 12. Watch the interview: https://t.co/a04njHP70K

[Ollin Biosciences @OllinBio]

We are excited to announce the closing of our oversubscribed $330 million Series B financing to advance global Phase 3 development of OLN324 and continued advancement of OLN102 for vision-threatening diseases. Read the full announcement: https://t.co/plIqDYl6Y5

[Ollin Biosciences @OllinBio]

Learn more: https://t.co/8yNBJhBNPn

[Ollin Biosciences @OllinBio]

What happens in Vegas? For us, it's presenting 20-week completion data from our JADE study at #CTS2026. We look forward to sharing final results from our randomized, head-to-head Phase 1b study comparing OLN324 to faricimab (Vabysmo®) in patients with #DME and #wAMD.

[Ollin Biosciences @OllinBio]

Learn more: https://t.co/IAmiDlPo4F

[Ollin Biosciences @OllinBio]

We will be participating in two upcoming investor conferences this June, including Jefferies Global Healthcare Conference and Evercore 2026 Emerging Private Biotech Conference.

[Ollin Biosciences @OllinBio]

#HealthyVisionMonth is a time to reflect on advancing care for people living with retinal diseases like wet AMD & DME. In our JADE study, OLN324 demonstrated durable control of disease, including sustained improvements in key anatomic outcomes. Learn more: https://t.co/Kb6CmvhlxP

[Ollin Biosciences @OllinBio]

Details: https://t.co/HLUil6PcmN

[Ollin Biosciences @OllinBio]

We look forward to participating in two upcoming investor conferences to share updates on our progress advancing next-generation therapies for vision-threatening diseases.

[Ollin Biosciences @OllinBio]

New final 20-week JADE data in DME and wAMD, showing favorable durability for OLN324 vs. faricimab (Vabysmo®) and more durable PED control, supporting its potential as a first-line treatment option. We look forward to Phase 3 studies this year. https://t.co/NKhXNoaAGx

[Ollin Biosciences @OllinBio]

#TED is a debilitating and potentially vision-threatening complication of Graves’ disease. OLN102 may offer patients improved treatment. We look forward to entering clinical development this year. https://t.co/Kb6CmvgNIh #AutoimmuneAwarenessMonth

[Ollin Biosciences @OllinBio]

Our CEO joined The BioHub Podcast to discuss his journey from physician-scientist to #biotech founder, and how those experiences shape Ollin’s approach today as we advance next-gen #ophthalmology therapies for serious, vision-threatening diseases. https://t.co/d84XBb0qfF

[Ollin Biosciences @OllinBio]

2B+ people live with vision impairment or blindness worldwide, according to @WHO. This #LowVisionAwarenessMonth, we’re proud to be pushing #ophthalmology innovation forward with the goal of delivering meaningful therapies for patients facing vision-threatening diseases.

[Ollin Biosciences @OllinBio]

Ollin SAB member Charles C. Wykoff, M.D., Ph.D.’s presentation of first-time results from our randomized, head-to-head JADE clinical study of OLN324 at Angiogenesis 2026 is now available. View the presentation materials on our website: https://t.co/y51GVOrvwJ

[Ollin Biosciences @OllinBio]

Full results from our randomized, head-to-head JADE clinical study of OLN324 will be presented for the first time at the 23rd Annual Angiogenesis, Exudation, and Degeneration 2026 virtual symposium on February 7. Learn more: https://t.co/t1nrQX7AEv

[Ollin Biosciences @OllinBio]

We were recently named the Healthtech & Bioinnovation winner of @MyABJ + @AustinInno's Fire Awards! This recognition celebrates companies driving innovation and is a meaningful nod to our mission to accelerate next-gen #ophthalmology therapies for vision-threatening diseases.

[Ollin Biosciences @OllinBio]

Thanks to everyone who joined us for CEO Jason Ehrlich’s corporate presentation at #JPM26. We're grateful for the chance to connect with partners and the healthcare community as we move forward in our mission to advance treatments for patients living with serious eye diseases.

[Ollin Biosciences @OllinBio]

#ICYMI: CEO Jason Ehrlich sat down with @endpointsnews to discuss recent positive topline data for OLN324, including superior anatomic efficacy, in a randomized trial vs. faricimab (Vabysmo®). Read the exclusive here: https://t.co/cxdhruAQI7

[Ollin Biosciences @OllinBio]

Pleased to share positive topline results with superior outcomes from our randomized, head-to-head Phase 1b JADE clinical study comparing OLN324, a next-gen VEGF/Ang2 bispecific antibody, with faricimab (Vabysmo®), in over 160 patients with #DME / #wAMD. https://t.co/Y5Gremw9JL